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Optimal management of seizures associated  
with tuberous sclerosis complex: current  
and emerging options
Abstract: Seizures are clinically significant manifestations associated with 79%–90% of patients 
with tuberous sclerosis complex. Often occurring within the first year of life in the form of infantile 
spasms, seizures interfere with neuropsychiatric, social, and cognitive development and carry 
significant individual and societal consequences. Prompt identification and treatment of seizures 
is an important focus in the overall management of tuberous sclerosis complex patients. Medical 
management, either after seizure onset or prophylactically in infants with electroencephalographic 
abnormalities, is considered first-line therapy. Vigabatrin and adrenocorticotropic hormone have 
emerged over the past few decades as mainstay pharmacologic modalities. Furthermore, emerging 
research on mammalian target of rapamycin inhibitors demonstrated promise for the management 
of seizures and subependymal giant cell astrocytoma. For appropriate surgical candidates with 
an epileptogenic zone associated with one or more glioneuronal hamartomas, ideally in nonelo-
quent cortex, resective surgery can be considered, which provides a cure in 56% of patients. For 
medically refractory patients who do not meet criteria for curative surgery, palliative surgical 
approaches focused on reducing seizure burden, in the form of corpus callosotomy and vagus 
nerve stimulation, are alternative management options. Lastly, the ketogenic diet, a reemerging 
therapy based on the anticonvulsant effects of ketone bodies, can be utilized independently or in 
conjunction with other treatment modalities for the management of difficult-to-treat seizures.
Keywords: epilepsy, adrenocorticotropic hormone, vigabatrin, mammalian target of rapamycin, 
ketogenic diet, vagus nerve stimulation
Introduction
Tuberous sclerosis complex (TSC) is an autosomal dominant neurocutaneous 
disorder characterized by the formation of hamartomas in multiple organ systems. 
TSC is estimated to affect 25,000–40,000 individuals in the United States and 1–2 
million individuals worldwide, with a prevalence of 1 in 6,000 live births.1
TSC1 or TSC2 mutations are found in over 85% of patients with TSC, either through 
autosomal dominant inheritance, de novo mutations, or rarely, gonadal mosaicism.2 
De novo mutations account for approximately 80% of TSC cases.3 The prevalence of 
TSC2 mutations is four times as common as TSC1 mutations among de novo cases 
and is approximately equal among familial TSC cases.4
TSC1, located on chromosome 9, codes for the hamartin protein, which is widely 
expressed in normal tissues. TSC2, located on chromosome 16, codes for the tuberin 
protein, which is expressed ubiquitously in all tissues. These two proteins interact 
in the Golgi complex, and the hamartin–tuberin complex acts as a tumor-suppressor 
protein through the Ras homologue enriched in brain protein to limit activation of the 
mammalian target of rapamycin (mTOR) complex 1. In TSC, inadequate suppression 
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of the mTOR complex 1 leads to abnormal cellular growth, 
proliferation, and protein synthesis.5–7 The severity and phe-
notype of TSC among individuals varies due to mosaicism, 
differences between TSC1 and TSC2 genes, and a variety 
of mutation types found in each gene.
The central nervous system is one of the most commonly 
affected systems in TSC. Brain pathology includes subependy-
mal nodules or subependymal giant cell astrocytoma (SEGA), 
glioneuronal hamartomas (cortical tubers), and white matter 
heterotopia. These findings are present in approximately 
90% of children with TSC and are associated with abnormal 
cognitive and seizure development.8,9 Due to the associa-
tions between epilepsy, development, and neuropsychiatric 
outcome, prompt evaluation and management of seizures is 
a clear focus of interest. In this article, the medical, surgical, 
and emerging management options will be discussed.
Seizures in TSC
Seizures are the most common presenting features of 
TSC, affecting 73%–90% of patients in population-based 
studies.8,10,11 The majority (63%) of TSC patients experience 
seizure onset within the first year of life, although adults 
without seizure history continue to be at risk, with 12% of 
adults in this subgroup later developing epilepsy.8,12 Epi-
lepsy develops in 96%–99% of TSC patients with a single 
seizure.11,12 Infantile spasm (IS) is the most common initial 
seizure subtype, although 54% of TSC patients develop mul-
tiple seizure types, including simple partial, complex partial, 
and secondary generalized seizures.12,13 IS, characterized 
by hypsarrhythmia on electroencephalography (EEG) and 
Lennox-Gastaut syndrome, characterized by frequent seizure 
activity of different morphology, are significant risk factors 
for the development of medically refractory epilepsy.
In patients with TSC, seizures are closely intertwined 
with global development. Specifically, cognitive disability 
is associated with a history of IS, refractory seizures, and 
to a lesser extent, the number or volume of glioneuronal 
hamartomas. A newly recognized entity of TSC-associated 
neuropsychiatric disorders describes the interrelated clinical 
manifestations of cerebral dysfunction, including aggressive 
behaviors, autism spectrum disorders, intellectual disabilities, 
psychiatric disorders, neuropsychological deficits as well as 
school and occupational difficulties.14 In a population-based 
study of TSC patients with early-onset epilepsy, refractory 
seizures (55%), intellectual disability (80%), and autism 
(30%) were prevalent.15 It is evident that a complex relation-
ship exists between TSC, epilepsy, treatment of epilepsy, 
and neuropsychiatric outcomes.
In addition to interference with neuropsychiatric devel-
opment, children with epileptic encephalopathy experience 
significant sleep disturbance patterns. This was manifested 
in altered sleep-related polysomnography parameters includ-
ing reduced total sleep time and sleep percentage, increased 
number of awakenings, increased rate in stage shifting, and 
higher rapid eye movement latency.16
Due to the importance of early recognition and manage-
ment of seizures, all TSC patients should undergo a baseline 
EEG evaluation. If it is abnormal, or in the case of patients 
exhibiting TSC-associated neuropsychiatric disorders, 
a 24-hour video EEG should be considered to assess for 
unrecognized or subclinical seizure activity.17 Furthermore, 
all patients with suspected TSC, regardless of age, should 
undergo brain magnetic resonance (MR) imaging at diagnosis 
and every 1–3 years until age 25 for surveillance of cerebral 
pathology.18
The characteristic brain lesion in TSC is SEGA, which 
is a World Health Organization grade 1, slow-growing 
tumor that usually arises in the periventricular area, some-
times from subependymal nodules.19 Due to its propensity 
toward growth near the foramen of Monro, it carries a 
clinically significant risk of morbidity and mortality from 
acute hydrocephalus, which is directly proportional to the 
SEGA volume.20 Secondly, cortical glioneuronal hama-
rtomas are composed histologically of enlarged atypical 
and disorganized neuronal and glial elements with astro-
cytosis. Because glioneuronal hamartomas form during 
embryogenesis, disruption of normal cortical development 
and function occurs early in gestation, leading to a pre-
disposition to seizures and cognitive deficits. The number 
and volume of tubers, as demonstrated by the tuber/brain 
proportion, have been linked to poor intelligence and cogni-
tive indices.21,22 Additionally, a subgroup of cyst-like tubers 
that show low signal intensity on fluid-attenuated inversion 
recovery and T1-weighted sequences and increased signal 
on T2-weighted sequences are associated with increased 
frequency of IS, epilepsy, and refractory epilepsy, and may 
represent a more epileptogenic focus and aggressive seizure 
phenotype.23 Lastly, white matter heterotopia are radial lines 
extending from the ventricles to the cortex, often in relation 
with subependymal nodules, and are thought to represent 
demyelination, dysmyelination, or hypomyelination from 
a migrational disorder.24
Early management of seizures is important in preventing 
subsequent epileptic encephalopathy and in reducing the 
cognitive and neuropsychiatric consequences.25,26 In one 
study of long-term neurologic outcome of TSC children 
Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2023
Management of epilepsy in tuberous sclerosis complex
with early-onset epilepsy, a shorter duration between seizure 
onset and start of antiepileptic treatment led to reduced risk 
of epileptic encephalopathy (including autism and intellectual 
disability).15 In an open-label randomized trial, early imple-
mentation of antiepileptic drugs in TSC infants with multifo-
cal EEG abnormalities, before the onset of seizures, resulted 
in a higher ratio of seizure-free patients, lower incidence of 
drug-resistant epilepsy, and lower number of patients requir-
ing polytherapy at 24 months of age.27 Although no standards 
exist, some clinicians advocate for prophylactic treatment of 
seizures based on this data. Comprehensive assessment in 
a center familiar with TSC management, involvement of a 
multidisciplinary team, and early initiation of treatment are 
considered key principles in the management of seizures in 
the TSC population.
Medical management
Adrenocorticotropic hormone (ACTH) and vigabatrin 
(VGB) are considered mainstay therapies for the treatment 
of seizures in TSC patients. Over the past few decades, 
emerging clinical evidence has supported the use of VGB 
as a first-line agent for TSC patients with IS. However, the 
adverse event of retinal toxicity remains a clinically relevant 
consideration.
Other medications can be considered for other seizure 
types, including carbamazepine for partial or complex 
partial seizures and rufinamide for focal or atonic seizures. 
Furthermore, there is emerging evidence supporting the use 
of mTOR inhibitors for the treatment of seizures in TSC 
patients with SEGA.
ACTH
ACTH, in addition to steroids (hydrocortisone, prednisone, 
or dexamethasone), has been used since the 1950s for the 
treatment of IS and Lennox-Gastaut syndrome. ACTH has 
demonstrated superior efficacy in comparison to steroids and 
is considered one of the first-line therapies for TSC-related 
seizures. In addition to stimulating the release of adrenal 
glucocorticoids, ACTH also suppresses the production of 
the stress-activated neuropeptide corticotropin-releasing 
hormone (CRH) through steroid-independent activation of 
central melanocortin receptors.28
In prospective trials of ACTH therapy for IS, cessation 
of seizures occurred in 42%–87% of infants, with increased 
efficacy in patients with cryptogenic IS compared to 
symptomatic IS (Table 1). The time from initiation of treat-
ment to cessation of seizures averaged from 7 to 12 days. 
In some cases, the effects of ACTH were found to persist 
after therapy discontinuation. Two prospective randomized 
controlled trials demonstrated that the efficacy of low dose 
ACTH therapy (either 0.2 IU/kg/day or 20–30 IU/day) 
was comparable to higher dose therapy and resulted in 
decreased adverse effects.29,30 Although there is insuf-
ficient evidence to precisely define the optimum ACTH 
dose and duration, clinicians can consider a 2-week course 
of ACTH at 20–30 IU/day, followed by a careful taper to 
discontinuation.31,32
Adverse effects occurred in 37%–85% of treated patients, 
most commonly being hypertension, immune suppression 
and infection, electrolyte imbalance, gastrointestinal dis-
turbances, ocular opacities, hypertrophic cardiomyopathy, 
cerebral atrophy, and growth impairment.33,34 A transient 
cushingoid appearance, hirsutism, irritability, and sleep 
disorders were also observed. Patients receiving ACTH 
treatment should be monitored closely for hypertension, 
electrolyte abnormalities, and infections.
vGB
VGB is an antiepileptic drug that inhibits the catabolism of 
gamma-aminobutyric acid (GABA) by irreversibly inhibiting 
GABA transaminase. VGB was approved by the US Food and 
Drug Administration (FDA) in 2009 as an adjunctive therapy 
for adult patients with refractory partial complex seizures 
and as monotherapy for pediatric patients aged 1 month to 
2 years with IS. It has emerged as a first-line treatment for 
TSC patients with IS.
VGB has shown efficacy in the treatment of TSC 
patients with IS and partial seizures in a number of retro-
spective and prospective studies, with a response rate of 
73%–96%.35 In a retrospective review of partial seizures, 
25% of patients became seizure-free or experienced a 
90% decrease in seizure frequency with the addition 
of VGB to their regimens.36 Children with epilepsy onset 
after 1 year of age were most likely to demonstrate a good 
response to VGB treatment. Even in the case of treatment-
resistant children (to carbamazepine, benzodiazepines, 
and sodium valproate) with IS, the addition of VGB led 
to seizure reduction in the majority of children, while 
43% showed complete suppression of spasms, the best 
short- and long-term outcomes observed in those with 
TSC.37 Prospective trials comparing VGB and ACTH 
also demonstrated its superiority in seizure control, time 
to control of symptoms, and in some cases favorable side 
effect profile (Table 1). Therefore, VGB has been identified 
by many countries as the first-line medical therapy for the 
treatment of TSC-related seizures.
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The optimal dosage of VGB is unclear, although a range 
of 18–200 mg/kg/day has been used in literature.32 Two ran-
domized trials demonstrated that higher (100–148 mg/kg/day) 
doses of VGB led to increased seizure cessation and shorter 
time to response compared to lower doses of therapy.38,39 The 
US consensus report on the management of IS recommends 
initial commencement of VGB at a dose of 50 mg/kg/day, 
escalating to 100–150 mg/kg/day as required for clinical 
response.31
Adverse events of VGB include somnolence, hypo-
tonia, weight gain, excitation, and insomnia. The most 
significant adverse effect is peripheral visual field defect 
from retinal cone and amacrine cell dysfunction. The 
prevalence varies according to patient age and extent of 
exposure to VGB and is approximately 25%–50% in adults, 
15% in children, and 15%–31% in infants.40 For patients 
initiated on VGB treatment, age-appropriate visual field 
testing is required at baseline and then repeated at inter-
vals in patients who continue therapy. VGB has also been 
reported to produce MR imaging abnormalities in infants 
treated for IS.41,42 These abnormalities, including hyperin-
tense lesions on T2-weighted images with restricted diffu-
sion on diffusion-weighted imaging in the basal ganglia, 
thalamus, brainstem, and dentate nucleus appear to be a 
subclinical, dose-related phenomenon that resolves with 
discontinuation of VGB.
The time from initiation of therapy to cessation of 
spasms ranged from 12 to 35 days; during this time, the 
risk of peripheral visual field defect development is low.32 
VGB should be discontinued if no clinical improvement 
is observed within 12 weeks. If patients have a meaning-
ful reduction in seizures or achieve seizure freedom, then 
the clinician and patient or caregiver must determine the 
benefits and risks of VGB therapy continuation. Mixed evi-
dence exist for discontinuation of VGB therapy following a 
period of clinical benefit. Some data suggest that VGB can 
be withdrawn in children who have been seizure-free for 
6 months,43 although other literature revealed spasm relapse 
after therapy discontinuation.44
mTOR inhibitors
mTOR is a protein kinase that controls cell growth, prolif-
eration, and survival. mTOR inhibitors bind to a domain 
separate from the catalytic site and inhibit a subset of mTOR 
functions. Sirolimus (rapamycin) and everolimus have been 
shown to be effective in the treatment of upregulation in can-
cers, and preliminary data for its use in the TSC population 
are promising.45,46 Everolimus was recently approved by the 
FDA in 2010 to treat SEGA in TSC following encouraging 
animal and human clinical data.
Case studies of TSC patients with medically refractory 
epilepsy and SEGA demonstrated dramatic reduction of 
seizure frequency and SEGA size with the administration of 
sirolimus and everolimus.47–49 A study involving five TSC 
patients with either SEGA or pilocytic astrocytoma who 
were treated with oral sirolimus demonstrated either lesional 
regression or necrosis. One of these patients had regrowth of 
a SEGA after having received sirolimus treatment that was 
interrupted for 4 months.50 A Phase II trial has demonstrated 
clinically relevant reductions of SEGA volume, including 
mean reductions of $30% from baseline in 75% of patients 
and $50% from baseline in 32% of patients.51 The overall 
frequency of clinical seizures and electrographic seizures, 
as assessed by 24-hour video EEG, was also significantly 
decreased at 6 months. No patients developed new lesions, 
worsening hydrocephalus, or evidence of increased intrac-
ranial pressure, and no patients required surgical resection 
or other SEGA treatment. In a Phase III double-blind ran-
domized controlled trial of 177 patients, 42% of patients 
had reductions in total SEGA volume by $50%. Most 
importantly, the reduction in SEGA volume was maintained 
in patients who received everolimus for $3 years, and a 
reduction of $30% in the volume of the primary SEGA 
lesion was maintained for a median duration of 24 months.52 
Furthermore, diffusion tensor imaging showed improvements 
from baseline in the integrity of normal-looking white matter 
at 12 and 18 months.
Adverse effects of mTOR inhibitors include immuno-
suppression. In the Phase III trial, 49% of patients receiving 
everolimus had adverse events requiring dose reduction or 
temporary interruption of treatment. Most were grade 1–2 
adverse effects consisting of gastritis, mouth ulceration, 
pyrexia, and pneumonia. No adverse events led to discontinu-
ation from the study, and no patients died during the study.52 
mTOR inhibitors have emerged as a promising treatment 
modality that may play a large role in the treatment paradigm 
of TSC patients.
Surgical management
Medical management of TSC-associated epilepsy is con-
sidered first-line therapy although some patients remain 
medically refractory. In one population-based study, 37% 
of patients had drug-resistant epilepsy.11 In this subset 
of patients, there may be a role for curative resective 
strategies or palliative disconnective or neuromodulatory 
strategies.
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Resective strategies
If an epileptogenic zone (EZ) associated with one or more gli-
oneuronal hamartomas, ideally in noneloquent cortex, can be 
localized, resective surgery may be offered as a cure. Resec-
tive surgery may be offered in the form of tuberectomy(ies), 
lobectomy, multilobar resection, and hemispherectomy. 
Determination of surgical candidacy, technique, and specific 
risks of the operation is a complex process requiring multi-
disciplinary collaboration. The groups’ recommendation is 
presented to the child and/or parent, who must ultimately be 
willing to accept the risks in hopes of attaining a good seizure 
outcome. Although similar principles of epilepsy surgery are 
utilized, the evaluation and ultimate recommendation for 
each patient is variable from institution to institution and are 
influenced by personal expertise and local experience with 
biotechnology (positron emission tomography, single-photon 
emission computed tomography, magnetoencephalography, 
and invasive EEG) available for localization of the EZ.
If resective surgery is an option, 56% of these patients 
may achieve seizure freedom following an operation.53 Other 
benefits include the possibility of decreasing or discontinuing 
antiepileptic drugs, ability to obtain/retain employment, abil-
ity to drive, improved independent functioning, and improved 
social relationships. Resective strategies still leave a large 
proportion of children (40%) with ongoing seizures. The 
major surgical morbidity rate is approximately 3%, which 
includes early postoperative death (secondary to hemorrhage, 
infection, and hydrocephalus) and late postoperative death 
(unexplained or related to seizures).
Given the invasiveness and irreversibility of surgical 
resection, it is of utmost importance to develop strategies to 
identify appropriate candidates. An individual participant 
data meta-analysis was performed to identify such predictors. 
Predictors of favorable seizure outcomes (Engel classification 
1 or 2; Table 2) following resective epilepsy surgery include 
absence of generalized seizure semiology, mild or no devel-
opmental delay, unifocal ictal scalp EEG abnormality, and 
EEG/MR imaging concordance.53 However, there are several 
important challenges in identification of predictors of seizure 
outcome in these children, the two most important being the 
rare incidence of disease and variability between centers in 
determining epilepsy surgery candidacy.
palliative strategies
The goal of palliative surgical approaches toward epilepsy is 
to control the symptoms or reduce seizure burden and sub-
sequently increase the quality of life. Palliative techniques 
include disconnective (corpus callosotomy [CC]) and 
 neuromodulatory (vagus nerve stimulation [VNS]) proce-
dures for the relief of seizure frequency.
CC
CC is a disconnective procedure characterized by division of 
the corpus callosum to limit the spread of ictal discharges and 
reduce the occurrence of generalized epileptic symptomatol-
ogy. The indications for CC are primarily frontal and bilater-
ally generated seizures. TSC patients with atonic seizures were 
the most responsive to CC.54 Seizure remission was achieved 
in 90% of TSC patients who underwent complete CC and 67% 
who underwent partial CC.54 Prior to offering CC, a thorough 
evaluation is required to ensure that there are no clearly defined 
focal EZ that could be amenable to a resective strategy. The 
benefits of CC over VNS include its availability, lower cost, 
and freedom from hardware-related complications. The limita-
tions include its invasiveness and irreversibility.
Specific surgical complications from a CC include injury 
to the superior sagittal sinus and bridging veins, perical-
losal artery ischemia, cingulate contusions, and bilateral 
mesiofrontal damage. CC is associated with a disconnection 
syndrome, which includes the inability to name objectives 
presented to the left hemifield, left hemi alexia, left hemiano-
pia, unilateral tactile anomia, and unilateral left agraphia. The 
overall morbidity is 5% while the mortality is 1% from this 
procedure.54 To minimize morbidity incurred from a discon-
nection syndrome, some physicians may elect to perform an 
anterior two-thirds CC prior to consideration of a full CC, 
if the seizures continue to be intractable. However, recent 
observational studies have supported a one-stage complete 
CC procedure, especially in severely affected or lower-
functioning children, for improved seizure control.55–57
VNS
An alternative palliative strategy includes surgery for 
neuromodulation in the form of VNS. Children with TSC 
and medically intractable epilepsy who are not considered 
Table 2 Engel classification of seizure outcomes following surgical 
resection
Class i Seizure free or no more than a few early, 
nondisabling seizures; or seizures upon drug 
withdrawal only
Class ii Disabling seizures occur rarely during a period of at 
least 2 years; disabling seizures may have been more 
frequent soon after surgery; nocturnal seizures
Class iii worthwhile improvement; seizure reduction for 
prolonged periods but less than 2 years
Class iv No worthwhile improvement; some reduction, no 
reduction, or worsening are possible 
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candidates for a resective procedure may be candidates for 
VNS implantation. In 1997, the VNS Therapy System™ was 
approved by the FDA as adjunctive therapy for adults and 
adolescents over 12 years of age whose partial-onset seizures 
were refractory to antiepileptic drugs. The main indications of 
VNS include nonlocalizable medically intractable epilepsy, 
those that fail surgical resection, or who have bilateral cortical 
localization. Similar to CC, VNS plays an important role in 
the treatment of atonic seizures.
The vagus nerve comprises approximately 20% efferent 
fibers and 80% afferent fibers, which serve as the target of 
VNS.58 Afferent vagal pathways lead to bilateral synapses on 
the nucleus of the solitary tract and to various cerebral regions 
involved in seizure generation. Vagus nerve pathways of 
seizure modulation of significance include projections to 
the pontine parabrachial nucleus, the parabrachial nucleus, 
and the locus ceruleus. Animal studies have revealed anti-
epileptogenic properties of VNS through a variety of mecha-
nisms, including abortion of ongoing seizures, acute seizure 
prophylaxis, chronic seizure prophylaxis, and inhibition of 
epileptogenesis in animal models of seizure kindling.59–65
The procedure involves an anterior cervical incision where 
the electrode leads are wrapped along the left vagus nerve in 
the carotid sheath. A separate subclavicular incision is made 
where the pulse generator is inserted into a subcutaneous 
pocket. Adverse effects include voice alteration, hoarseness, 
and coughing during stimulation. Following insertion, the 
VNS requires programming and lifetime follow-up with an 
epileptologist and intermittent battery change, the frequency 
of which is determined by the stimulation parameters. The 
patient is discharged from hospital with a magnet that can 
be held over the pulse generator to abort seizures.
VNS is generally efficacious, with limited adverse events. 
Four reviews with a combined total of 38 children demon-
strated VNS as an effective and well-tolerated adjunctive ther-
apy for refractory seizures. Overall, 72% reported at least 50% 
seizure reduction.66–69 Furthermore, a significant improvement 
in quality of life and neuropsychological outcome (attention, 
cognition, behavior, mood) was recognized.70,71
Ketogenic diet
The ketogenic diet (KD) is a high fat, adequate protein, 
and low carbohydrate diet that results in a state of ketosis. 
Initially developed in the early 1920s,72 the KD had fallen 
into disuse during the 1970s with the rapid development 
of new antiepileptic drugs. In the past decade, resurgence 
of its therapeutic use had a major impact on the treatment 
of refractory seizures.
The KD leads to changes in plasma levels of ketones, 
insulin, glucose, glucagon, and free fatty acids. Formation 
of ketone bodies in the liver from long and medium-chain 
fatty acids have a direct anticonvulsant effect when crossing 
the blood–brain barrier. Increased mitochondrial biogenesis, 
oxidative phosphorylation, enhanced GABA levels, reduced 
neuronal excitability and firing, and stabilized synaptic func-
tion have been shown to occur in patients on the KD.73,74 
Additionally, the roles of carbohydrate reduction, activation 
of adenosine triphosphate-sensitive potassium channels by 
mitochondrial metabolism, inhibition of the mTOR pathway, 
and inhibition of glutamatergic excitatory synaptic transmis-
sion have been described.75,76
Animal studies and human clinical studies of the KD 
have both demonstrated efficacy in the treatment of medi-
cally refractory seizures. In one study of 150 medically 
refractory children (on an average of 6.2 medications), 
improved seizure control was observed immediately after 
initiation of the KD and during a 3–6 year follow-up.13,14 
Twelve months after initiating the diet, 7% of the children 
were seizure free and another 20% had $90% decrease in 
seizures; 3–6 years later, 27% of these same children had 
fewer or no seizures. Several recent meta-analyses of the 
KD for seizure control revealed complete seizure cessation 
achieved in 10%–16%, $90% reduction in seizures in 32%, 
and $50% reduction in seizures in 33%–56%.77–80 In one 
small study of 12 TSC patients, 92% of children had a $50% 
reduction in seizures at 6 months, and 67% had a $90% 
reduction at 5 months.81 The specific effects of the KD was 
described in a study of three boys with TSC and refractory 
partial seizures, who started the diet at 3.5–6 years of age.82 
The KD effectively and completely controlled seizures in 
two patients and significantly decreased the frequency of 
atonic seizures in the third patient while he was between 
multistage surgical procedures. The only randomized 
controlled trial for the role of the KD in medically refrac-
tory epilepsy demonstrated statistically significant seizure 
control: at 3 months, 38% had $50% reduction in seizures 
and 7% experienced $90% reduction.83
Early-onset adverse effects associated with the KD include 
acidosis, hypoglycemia, gastrointestinal distress, dehydration, 
and lethargy. They are typically transient and easily managed 
and are minimized if patients are not fasted. Later adverse 
effects include dyslipidemia, kidney stones, acidosis, growth 
retardation, and decreased bone density.84 Common reasons 
for diet intolerability or discontinuation included 50% 
seizure reduction (47%), diet restrictiveness (16%), and 
incurrent illness or diet side effects (13%).80
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Conclusion
Seizures associated with TSC carry significant individual and 
societal impact. Often arising early in life, they are difficult to 
treat and interfere with normal cognitive and neuropsychiatric 
development. This review focused on the medical, surgical, 
and emerging management modalities for seizures in the TSC 
population. Mainstay pharmacologic treatments of ACTH and 
VGB have emerged as first-line therapies for TSC patients with 
IS. Emerging evidence for mTOR inhibitors have supported its 
role for the treatment of epilepsy and SEGA in TSC patients. 
For individuals with a localized EZ, resective strategies can 
be considered for cure. Other surgical strategies, including 
CC and VNS, can be used for palliative purposes to decrease 
seizure frequency. Lastly, the KD is a reemerging therapy for 
difficult-to-control seizures of all types. Although the treatment 
of seizures in TSC patients is complex and often multimodal, 
groundwork over the past few decades has advanced this field 
significantly. Emerging research in both medical and surgical 
modalities continues to hold promise for improved medical 
and developmental outcomes in this population.
Disclosure
The authors report no conflicts of interest in this work.
References
 1. National Institute of Neurological Disorders and Stroke. Tuberous 
sclerosis fact sheet. NIH publication number 07-1846 2014 [webpage 
on the Internet]. Bethesda, MD: National Institutes of Health; 2014 
[updated April 16, 2014]. Available from: http://www.ninds.nih.gov/
disorders/tuberous_sclerosis/detail_tuberous_sclerosis.htm
 2. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. 
N Engl J Med. 2006;355(13):1345–1356.
 3. Roach ES, Sparagana SP. Diagnosis of tuberous sclerosis complex. 
J Child Neurol. 2004;19(9):643–649.
 4. Au KS, Williams AT, Roach ES, et al. Genotype/phenotype correlation 
in 325 individuals referred for a diagnosis of tuberous sclerosis complex 
in the United States. Genet Med. 2007;9(2):88–100.
 5. Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. 2008; 
372(9639):657–668.
 6. Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switch-
board controlling cell growth. Biochem J. 2008;412(2):179–190.
 7. Chan JA, Zhang H, Roberts PS, et al. Pathogenesis of tuberous scle-
rosis subependymal giant cell astrocytomas: biallelic inactivation of 
TSC1 or TSC2 leads to mTOR activation. J Neuropathol Exp Neurol. 
2004;63(12):1236–1242.
 8. Yates JR, Maclean C, Higgins JN, et al; Tuberous Sclerosis 2000 Study 
Group. The Tuberous Sclerosis 2000 Study: presentation, initial assess-
ments and implications for diagnosis and management. Arch Dis Child. 
2011;96(11):1020–1025.
 9. Inoue Y, Nemoto Y, Murata R, et al. CT and MR imaging of cerebral 
tuberous sclerosis. Brain Dev. 1998;20(4):209–221.
 10. Joinson C, O’Callaghan FJ, Osborne JP, Martyn C, Harris T, 
 Bolton PF. Learning disability and epilepsy in an epidemiological 
sample of individuals with tuberous sclerosis complex. Psychol Med. 
2003;33(2):335–344.
 11. Vignoli A, La Briola F, Turner K, et al. Epilepsy in TSC: certain etiology 
does not mean certain prognosis. Epilepsia. 2013;54(12):2134–2142.
 12. Chu-Shore CJ, Major P, Camposano S, Muzykewicz D, Thiele EA. 
The natural history of epilepsy in tuberous sclerosis complex. Epilepsia. 
2010;51(7):1236–1241.
 13. Riikonen R, Simell O. Tuberous sclerosis and infantile spasms. Dev 
Med Child Neurol. 1990;32(3):203–209.
 14. de Vries P. Neurodevelopmental, psychiatric and cognitive aspects 
of tuberous sclerosis complex. In: Kwiatkowsi DJ, Whittemore VH, 
Thiele EA, editors. Tuberous Sclerosis Complex: Genes, Clinical 
Features. Weinheim: Wiley-Blackwell. 2010:229–267.
 15. Cusmai R, Moavero R, Bombardieri R, Vigevano F, Curatolo P. Long-
term neurological outcome in children with early-onset epilepsy associ-
ated with tuberous sclerosis. Epilepsy Behav. 2011;22(4):735–739.
 16. Carotenuto M, Parisi P, Esposito M, Cortese S, Elia M. Sleep alterations 
in children with refractory epileptic encephalopathies: a polysomno-
graphic study. Epilepsy Behav. 2014;35:50–53.
 17. Curatolo P, Jóźwiak S, Nabbout R; TSC Consensus Meeting for SEGA 
and Epilepsy Management. Management of epilepsy associated with 
tuberous sclerosis complex (TSC): clinical recommendations. Eur J 
Paediatr Neurol. 2012;16(6):582–586.
 18. Krueger DA, Northrup H; International Tuberous Sclerosis Complex 
Consensus Group. Tuberous sclerosis complex surveillance and 
management: recommendations of the 2012 International Tuber-
ous Sclerosis Complex Consensus Conference. Pediatr Neurol. 
2013;49(4):255–265.
 19. Goh S, Butler W, Thiele EA. Subependymal giant cell tumors in tuber-
ous sclerosis complex. Neurology. 2004;63(8):1457–1461.
 20. de Ribaupierre S, Dorfmüller G, Bulteau C, et al. Subependymal  giant-cell 
astrocytomas in pediatric tuberous sclerosis disease: when should we 
operate? Neurosurgery. 2007;60(1):83–89; discussion 89–90.
 21. Goodman M, Lamm SH, Engel A, Shepherd CW, Houser OW, Gomez MR. 
Cortical tuber count: a biomarker indicating neurologic severity of 
tuberous sclerosis complex. J Child Neurol. 1997;12(2):85–90.
 22. Jansen FE, Vincken KL, Algra A, et al. Cognitive impairment in tuber-
ous sclerosis complex is a multifactorial condition. Neurology. 2008; 
70(12):916–923.
 23. Chu-Shore CJ, Major P, Montenegro M, Thiele E. Cyst-like tubers 
are associated with TSC2 and epilepsy in tuberous sclerosis complex. 
Neurology. 2009;72(13):1165–1169.
 24. Iwasaki S, Nakagawa H, Kichikawa K, et al. MR and CT of tuberous 
sclerosis: linear abnormalities in the cerebral white matter. AJNR Am 
J Neuroradiol. 1990;11(5):1029–1034.
 25. Bombardieri R, Pinci M, Moavero R, Cerminara C, Curatolo P. Early 
control of seizures improves long-term outcome in children with tuber-
ous sclerosis complex. Eur J Paediatr Neurol. 2010;14(2):146–149.
 26. Camposano SE, Major P, Halpern E, Thiele EA. Vigabatrin in the treat-
ment of childhood epilepsy: a retrospective chart review of efficacy and 
safety profile. Epilepsia. 2008;49(7):1186–1191.
 27. Jóźwiak S, Kotulska K, Domańska-Pakieła D, et al. Antiepileptic 
treatment before the onset of seizures reduces epilepsy severity and 
risk of mental retardation in infants with tuberous sclerosis complex. 
Eur J Paediatr Neurol. 2011;15(5):424–431.
 28. Brunson KL, Avishai-Eliner S, Baram TZ. ACTH treatment of infantile 
spasms: mechanisms of its effects in modulation of neuronal excitability. 
Int Rev Neurobiol. 2002;49:185–197.
 29. Yanagaki S, Oguni H, Hayashi K, et al. A comparative study of high-
dose and low-dose ACTH therapy for West syndrome. Brain Dev. 1999; 
21(7):461–467.
 30. Hrachovy RA, Frost JD, Glaze DG. High-dose, long-duration versus 
low-dose, short-duration corticotropin therapy for infantile spasms. 
J Pediatr. 1994;124(5 Pt 1):803–806.
 31. Pellock JM, Hrachovy R, Shinnar S, et al. Infantile spasms: a U.S. 
consensus report. Epilepsia. 2010;51(10):2175–2189.
 32. Mackay MT, Weiss SK, Adams-Webber T, et al; American Acad-
emy of Neurology; Child Neurology Society. Practice parameter: 
medical treatment of infantile spasms: report of the American Acad-
emy of Neurology and the Child Neurology Society. Neurology. 
2004;62(10):1668–1681.
Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2029
Management of epilepsy in tuberous sclerosis complex
 33. Riikonen R, Donner M. ACTH therapy in infantile spasms: side effects. 
Arch Dis Child. 1980;55(9):664–672.
 34. Lombroso CT. A prospective study of infantile spasms: clinical and 
therapeutic correlations. Epilepsia. 1983;24(2):135–158.
 35. Aicardi J, Mumford JP, Dumas C, Wood S. Vigabatrin as initial therapy 
for infantile spasms: a European retrospective survey. Sabril IS Inves-
tigator and Peer Review Groups. Epilepsia. 1996;37(7):638–642.
 36. Friedman D, Bogner M, Parker-Menzer K, Devinsky O. Vigabatrin 
for partial-onset seizure treatment in patients with tuberous sclerosis 
complex. Epilepsy Behav. 2013;27(1):118–120.
 37. Chiron C, Dulac O, Beaumont D, Palacios L, Pajot N, Mumford J. 
Therapeutic trial of vigabatrin in refractory infantile spasms. J Child 
Neurol. 1991;Suppl 2:S52–S59.
 38. Elterman RD, Shields WD, Mansfield KA, Nakagawa J; US Infantile 
Spasms Vigabatrin Study Group. Randomized trial of vigabatrin in 
patients with infantile spasms. Neurology. 2001;57(8):1416–1421.
 39. Elterman RD, Shields WD, Bittman RM, Torri SA, Sagar SM, Collins SD. 
Vigabatrin for the treatment of infantile spasms: final report of a ran-
domized trial. J Child Neurol. 2010;25(11):1340–1347.
 40. Willmore LJ, Abelson MB, Ben-Menachem E, Pellock JM, Shields WD. 
Vigabatrin: 2008 update. Epilepsia. 2009;50(2):163–173.
 41. Pearl PL, Vezina LG, Saneto RP, et al. Cerebral MRI abnormalities 
associated with vigabatrin therapy. Epilepsia. 2009;50(2):184–194.
 42. Wheless JW, Carmant L, Bebin M, et al. Magnetic resonance imaging 
abnormalities associated with vigabatrin in patients with epilepsy. 
Epilepsia. 2009;50(2):195–205.
 43. Guideline for prescribing vigabatrin in children has been revised. Vigaba-
trin Paediatric Advisory Group. BMJ. 2000;320(7246):1404–1405.
 44. Kröll-Seger J, Kaminska A, Moutard ML, et al. Severe relapse of 
epilepsy after vigabatrin withdrawal: for how long should we treat 
symptomatic infantile spasms? Epilepsia. 2007;48(3):612–613.
 45. Zeng LH, Xu L, Gutmann DH, Wong M. Rapamycin prevents epi-
lepsy in a mouse model of tuberous sclerosis complex. Ann Neurol. 
2008;63(4):444–453.
 46. Ehninger D, Han S, Shilyansky C, et al. Reversal of learning deficits 
in a Tsc2+/- mouse model of tuberous sclerosis. Nat Med. 2008; 
14(8):843–848.
 47. Muncy J, Butler IJ, Koenig MK. Rapamycin reduces seizure frequency 
in tuberous sclerosis complex. J Child Neurol. 2009;24(4):477.
 48. Perek-Polnik M, Jóźwiak S, Jurkiewicz E, Perek D, Kotulska K. Effec-
tive everolimus treatment of inoperable, life-threatening subependymal 
giant cell astrocytoma and intractable epilepsy in a patient with tuberous 
sclerosis complex. Eur J Paediatr Neurol. 2012;16(1):83–85.
 49. Koenig MK, Butler IJ, Northrup H. Regression of subependymal giant 
cell astrocytoma with rapamycin in tuberous sclerosis complex. J Child 
Neurol. 2008;23(10):1238–1239.
 50. Franz DN, Leonard J, Tudor C, et al. Rapamycin causes regres-
sion of astrocytomas in tuberous sclerosis complex. Ann Neurol. 
2006;59(3):490–498.
 51. Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal 
giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010; 
363(19):1801–1811.
 52. Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of 
everolimus for subependymal giant cell astrocytomas associated 
with tuberous sclerosis complex (EXIST-1): a multicentre, ran-
domised, placebo-controlled phase 3 trial. Lancet. 2013;381(9861): 
125–132.
 53. Fallah A, Guyatt GH, Snead OC, et al. Predictors of seizure outcomes 
in children with tuberous sclerosis complex and intractable epilepsy 
undergoing resective epilepsy surgery: an individual participant data 
meta-analysis. PLoS One. 2013;8(2):e53565.
 54. Shimizu H. Our experience with pediatric epilepsy surgery focusing on 
corpus callosotomy and hemispherotomy. Epilepsia. 2005;46(Suppl 1): 
30–31.
Jalilian L, Limbrick DD, Steger-May K, Johnston J, Powers AK, Smyth 55. 
MD. Complete versus anterior two-thirds corpus callosotomy in chil-
dren: analysis of outcome. J Neurosurg Pediatr. 2010;6(3):257–266.
Kasasbeh AS, Smyth MD, Steger-May K, Jalilian L, Bertrand M, 56. 
Limbrick DD. Outcomes after anterior or complete corpus callosotomy 
in children. Neurosurgery. 2014;74(1):17–28.
Shim KW, Lee YM, Kim HD, Lee JS, Choi JU, Kim DS. Changing the 57. 
paradigm of 1-stage total callosotomy for the treatment of pediatric 
generalized epilepsy. J Neurosurg Pediatr. 2008;2(1):29–36.
Henry TR. Therapeutic mechanisms of vagus nerve stimulation. 58. Neurol-
ogy. 2002;59(6 Suppl 4):S3–S14.
McLachlan RS. Suppression of interictal spikes and seizures by stimula-59. 
tion of the vagus nerve. Epilepsia. 1993;34(5):918–923.
Woodbury DM, Woodbury JW. Effects of vagal stimulation on 60. 
experimentally induced seizures in rats. Epilepsia. 1990;31(Suppl 2): 
S7–S19.
Zabara J. Inhibition of experimental seizures in canines by repetitive 61. 
vagal stimulation. Epilepsia. 1992;33(6):1005–1012.
Lockard JS, Congdon WC, DuCharme LL. Feasibility and safety of 62. 
vagal stimulation in monkey model. Epilepsia. 1990;31(Suppl 2): 
S20–S26.
Takaya M, Terry WJ, Naritoku DK. Vagus nerve stimulation induces a 63. 
sustained anticonvulsant effect. Epilepsia. 1996;37(11):1111–1116.
Fernández-Guardiola A, Martínez A, Valdés-Cruz A, Magdaleno-64. 
Madrigal VM, Martínez D, Fernández-Mas R. Vagus nerve prolonged 
stimulation in cats: effects on epileptogenesis (amygdala electrical 
kindling): behavioral and electrographic changes. Epilepsia. 1999; 
40(7):822–829.
Magdaleno-Madrigal VM, Valdés-Cruz A, Martínez-Vargas D, et al. 65. 
Effect of electrical stimulation of the nucleus of the solitary tract on 
the development of electrical amygdaloid kindling in the cat. Epilepsia. 
2002;43(9):964–969.
Elliott RE, Carlson C, Kalhorn SP, et al. Refractory epilepsy in tuberous 66. 
sclerosis: vagus nerve stimulation with or without subsequent resective 
surgery. Epilepsy Behav. 2009;16(3):454–460.
Major P, Thiele EA. Vagus nerve stimulation for intractable epilepsy in 67. 
tuberous sclerosis complex. Epilepsy Behav. 2008;13(2):357–360.
Parain D, Penniello MJ, Berquen P, Delangre T, Billard C, Murphy JV. 68. 
Vagal nerve stimulation in tuberous sclerosis complex patients. Pediatr 
Neurol. 2001;25(3):213–216.
Zamponi N, Petrelli C, Passamonti C, Moavero R, Curatolo P. Vagus 69. 
nerve stimulation for refractory epilepsy in tuberous sclerosis. Pediatr 
Neurol. 2010;43(1):29–34.
Hallböök T, Lundgren J, Stjernqvist K, Blennow G, Strömblad LG, 70. 
Rosén I. Vagus nerve stimulation in 15 children with therapy resistant 
epilepsy; its impact on cognition, quality of life, behaviour and mood. 
Seizure. 2005;14(7):504–513.
Helmers SL, Wheless JW, Frost M, et al. Vagus nerve stimulation 71. 
therapy in pediatric patients with refractory epilepsy: retrospective 
study. J Child Neurol. 2001;16(11):843–848.
Bough KJ, Rho JM. Anticonvulsant mechanisms of the ketogenic diet. 72. 
Epilepsia. 2007;48(1):43–58.
Bough KJ, Wetherington J, Hassel B, et al. Mitochondrial biogenesis 73. 
in the anticonvulsant mechanism of the ketogenic diet. Ann Neurol. 
2006;60(2):223–235.
Danial NN, Hartman AL, Stafstrom CE, Thio LL. How does the 74. 
ketogenic diet work? Four potential mechanisms. J Child Neurol. 
2013;28(8):1027–1033.
Wilder RM. The effects of ketonemia on the course of epilepsy. 75. Mayo 
Clin Proc. 1921;2:307-308.
McDaniel SS, Rensing NR, Thio LL, Yamada KA, Wong M. The 76. 
ketogenic diet inhibits the mammalian target of rapamycin (mTOR) 
pathway. Epilepsia. 2011;52(3):e7–e11.
Levy RG, Cooper PN, Giri P. Ketogenic diet and other dietary treat-77. 
ments for epilepsy. Cochrane Database Syst Rev. 2012;3:CD001903.
Lefevre F, Aronson N. Ketogenic diet for the treatment of refractory 78. 
epilepsy in children: A systematic review of efficacy. Pediatrics. 2000; 
105(4):E46.
Keene DL. A systematic review of the use of the ketogenic diet in 79. 
childhood epilepsy. Pediatr Neurol. 2006;35(1):1–5.
Neuropsychiatric Disease and Treatment
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal
Neuropsychiatric Disease and Treatment is an international, peer-
reviewed journal of clinical therapeutics and pharmacology focusing 
on concise rapid reporting of clinical or pre-clinical studies on a 
range of neuropsychiatric and neurological disorders. This journal 
is indexed on PubMed Central, the ‘PsycINFO’ database and CAS, 
and is the official journal of The International Neuropsychiatric 
 Association (INA). The manuscript management system is completely 
online and includes a very quick and fair peer-review system, which 
is all easy to use. Visit http://www.dovepress.com/testimonials.php to 
read real quotes from published authors.
Neuropsychiatric Disease and Treatment 2014:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
2030
wang and Fallah
Henderson CB, Filloux FM, Alder SC, Lyon JL, Caplin DA. Efficacy 80. 
of the ketogenic diet as a treatment option for epilepsy: meta-analysis. 
J Child Neurol. 2006;21(3):193–198.
Kossoff EH, Thiele EA, Pfeifer HH, McGrogan JR, Freeman JM. 81. 
Tuberous sclerosis complex and the ketogenic diet. Epilepsia. 
2005;46(10):1684–1686.
Coppola G, Klepper J, Ammendola E, et al. The effects of the ketogenic 82. 
diet in refractory partial seizures with reference to tuberous sclerosis. 
Eur J Paediatr Neurol. 2006;10(3):148–151.
Neal EG, Chaffe H, Schwartz RH, et al. The ketogenic diet for the 83. 
treatment of childhood epilepsy: a randomised controlled trial. Lancet 
Neurol. 2008;7(6):500–506.
Freeman JM, Kossoff EH, Hartman AL. The ketogenic diet: one decade 84. 
later. Pediatrics. 2007;119(3):535–543.
Hrachovy RA, Frost JD, Kellaway P, Zion TE. Double-blind study 85. 
of ACTH vs prednisone therapy in infantile spasms. J Pediatr. 1983; 
103(4):641–645.
Baram TZ, Mitchell WG, Tournay A, Snead OC, Hanson RA, Horton EJ. 86. 
High-dose corticotropin (ACTH) versus prednisone for infantile 
spasms: a prospective, randomized, blinded study. Pediatrics. 
1996;97(3):375–379.
Zou LP, Wang X, Dong CH, Chen CH, Zhao W, Zhao RY. Three-week 87. 
combination treatment with ACTH + magnesium sulfate versus ACTH 
monotherapy for infantile spasms: a 24-week, randomized, open-label, 
follow-up study in China. Clin Ther. 2010;32(4):692–700.
Chiron C, Dumas C, Jambaqué I, Mumford J, Dulac O. Randomized 88. 
trial comparing vigabatrin and hydrocortisone in infantile spasms due 
to tuberous sclerosis. Epilepsy Res. 1997;26(2):389–395.
Vigevano F, Cilio MR. Vigabatrin versus ACTH as first-line treat-89. 
ment for infantile spasms: a randomized, prospective study. Epilepsia. 
1997;38(12):1270–1274.
Granström ML, Gaily E, Liukkonen E. Treatment of infantile spasms: 90. 
results of a population-based study with vigabatrin as the first drug for 
spasms. Epilepsia. 1999;40(7):950–957.
